LifeMD Dividend

Dividend criteria checks 0/6

LifeMD does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Payout ratio

Industry average yield	1.1%
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Earnings per share	-US$0.58
Dividend yield forecast in 3Y	n/a

Recent dividend updates

No updates

Recent updates

Is LifeMD (NASDAQ:LFMD) Using Debt Sensibly?

Apr 25

Even With A 29% Surge, Cautious Investors Are Not Rewarding LifeMD, Inc.'s (NASDAQ:LFMD) Performance Completely

Mar 30

LifeMD: Results And Guidance Point To Continued Strength In Weight Management Program

Mar 13

Take Care Before Jumping Onto LifeMD, Inc. (NASDAQ:LFMD) Even Though It's 34% Cheaper

Jan 05

Does This Valuation Of LifeMD, Inc. (NASDAQ:LFMD) Imply Investors Are Overpaying?

Dec 03

Investors Still Aren't Entirely Convinced By LifeMD, Inc.'s (NASDAQ:LFMD) Revenues Despite 38% Price Jump

Apr 17

Analysts Are Betting On LifeMD, Inc. (NASDAQ:LFMD) With A Big Upgrade This Week

Nov 17

LifeMD launches at-home screening kits for breast, colon cancers

Sep 14

LifeMD Non-GAAP EPS of -$0.22 beats by $0.01, revenue of $30.5M misses by $1.45M

Aug 11

LifeMD CEO Justin Schreiber - Disrupting Healthcare With Telemedicine

Jan 10

LifeMD: 4 Reasons You Should Avoid This Stock

Sep 29

LifeMD: Telehealth Growth Spectacular

Sep 17

LifeMD: 'Actual, Hard Numbers' Keep Us Bullish

Jul 13

Two class-action shareholder suits against LifeMD dropped

May 28

LifeMD (LFMD) Investor Presentation - Slideshow

May 01

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if LFMD's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LFMD's dividend payments have been increasing.

Dividend Yield vs Market

LifeMD Dividend Yield vs Market

How does LFMD dividend yield compare to the market?
Segment	Dividend Yield
Company (LFMD)	n/a
Market Bottom 25% (US)	1.6%
Market Top 25% (US)	4.8%
Industry Average (Healthcare Services)	1.1%
Analyst forecast in 3 Years (LFMD)	n/a

Notable Dividend: Unable to evaluate LFMD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LFMD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate LFMD's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as LFMD has not reported any payouts.

LifeMD Dividend

Dividend criteria checks 0/6

Key information

Recent dividend updates

Recent updates

LifeMD, Inc., Annual General Meeting, Jun 14, 2024

LifeMD, Inc. Appoints Calum Macrae to Its Board of Directors

LifeMD, Inc. to Report Q1, 2024 Results on May 08, 2024

Is LifeMD (NASDAQ:LFMD) Using Debt Sensibly?

Even With A 29% Surge, Cautious Investors Are Not Rewarding LifeMD, Inc.'s (NASDAQ:LFMD) Performance Completely

LifeMD, Inc. Provides Earnings Guidance for the First Quarter of 2024 and Revises Earnings Guidance for the Full Year of 2024

LifeMD: Results And Guidance Point To Continued Strength In Weight Management Program

Price target increased by 20% to US$12.20

LifeMD, Inc. to Report Q4, 2023 Results on Mar 11, 2024

LifeMD's 2024: Striking A Balance Between Rapid Expansion And Sustainability

LifeMD: A GLP-1 Play With A Kicker

LifeMD, Inc. Provides Earnings Guidance for the Fiscal Year 2024

Is LifeMD, Inc. (NASDAQ:LFMD) Potentially Undervalued?

Take Care Before Jumping Onto LifeMD, Inc. (NASDAQ:LFMD) Even Though It's 34% Cheaper

LifeMD, Inc. announced that it expects to receive $10.000001 million in funding from Jason Pharmaceuticals, Inc.

Does This Valuation Of LifeMD, Inc. (NASDAQ:LFMD) Imply Investors Are Overpaying?

Insufficient new directors

Lifemd, Inc. Announces Resignation of Bertrand Velge from His Position as Member of the Board of Directors

Consensus EPS estimates fall by 12%

LifeMD, Inc. Provides Revenue Guidance for the Fourth Quarter and for the Full Year 2023

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

LifeMD, Inc. to Report Q3, 2023 Results on Nov 08, 2023

Price target increased by 9.7% to US$8.50

Independent Director recently bought US$501k worth of stock

Consensus EPS estimates fall by 57%, revenue upgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

LifeMD, Inc. Provides Earnings Guidance for the Full Year 2023

New major risk - Share price stability

LifeMD, Inc. to Report Q2, 2023 Results on Aug 09, 2023

Price target increased by 46% to US$7.67

LifeMD, Inc. Appoints William J. Febbo to Its Board of Directors

Independent Director recently bought US$170k worth of stock

Chairman & CEO recently bought US$105k worth of stock

Lifemd, Inc. Provides Earnings Guidance for the Second Quarter 2023 and Full Year 2023

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

LifeMD, Inc. to Report Q1, 2023 Results on May 12, 2023

Investors Still Aren't Entirely Convinced By LifeMD, Inc.'s (NASDAQ:LFMD) Revenues Despite 38% Price Jump

Consensus EPS estimates upgraded to US$0.46 loss

Full year 2022 earnings: EPS and revenues miss analyst expectations

LifeMD, Inc. Appoints Dr. Joan Larovere to its Board of Directors

LifeMD, Inc. Appoints Jessica Friedeman as Chief Marketing Officer

No longer forecast to breakeven

Analysts Are Betting On LifeMD, Inc. (NASDAQ:LFMD) With A Big Upgrade This Week

Price target decreased to US$8.00

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

LifeMD, Inc. to Report Q3, 2022 Results on Nov 10, 2022

LifeMD, Inc. Appoints Bobby Jindal to the Board of Directors

LifeMD, Inc. Expands Primary Care Platform’s Diagnostic Capabilities with New At-Home Screening Kits For Early Warning Signs Of Cancer

LifeMD launches at-home screening kits for breast, colon cancers

Consensus EPS estimates fall by 15%

Forecast to breakeven in 2024

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

LifeMD, Inc. Provides Consolidated Earnings Guidance for the Third Quarter 2022 and Full Year 2022

LifeMD Non-GAAP EPS of -$0.22 beats by $0.01, revenue of $30.5M misses by $1.45M

LifeMD, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Consensus EPS estimates fall by 14%

Insider recently bought US$107k worth of stock

Lifemd, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2022

First quarter 2022 earnings: EPS and revenues miss analyst expectations

LifeMD, Inc. to Report Q1, 2022 Results on May 13, 2022

LifeMD, Inc., Annual General Meeting, Jun 16, 2022

Price target decreased to US$15.50

Forecast to breakeven in 2024

LifeMD, Inc. Provides Revenue Guidance for the First Quarter and Full Year of 2022

Full year 2021 earnings: EPS exceeds analyst expectations

LifeMD, Inc. to Report Fiscal Year 2021 Results on Mar 07, 2022

LifeMD, Inc. Launches Primary Care Platform Nationwide Following Beta Launch

LifeMD, Inc. Announces Appointment of Maria Stan as Controller and Principal Accounting Officer

Consensus forecasts updated

LifeMD, Inc. Provides Earnings Guidance for the Year 2022; Provides Earnings Guidance for the First Quarter of 2022

LifeMD, Inc. (NasdaqGM:LFMD) entered into a stock purchase agreement to acquire Cleared Technologies Pbc from a group of sellers for $77.2 million.

LifeMD CEO Justin Schreiber - Disrupting Healthcare With Telemedicine

Consensus forecasts updated

Insider recently bought US$194k worth of stock